

Management of Pregnant Women with Chronic Hepatitis B Virus (HBV) Infection

During Pregnancy:

1. Test all women for HBsAg anytime during pregnancy
2. Report all women with HBsAg+ and positive pregnancy test to the State of Alaska regardless of outcome of pregnancy. The Prenatal Reporting Form can be found on the Alaska Department of Health and Human Services site; [Perinatal Hepatitis B Prevention Program \(alaska.gov\)](https://perinatalreporting.alaska.gov/), or <https://dhss.alaska.gov/dph/Epi/iz/Pages/hbv/>.
3. For those women who are known to have chronic HBV (HBsAg-positive), perform liver function test (LFT) panel, AFP and HBV DNA once at any time during pregnancy
 - a. If HBV DNA is > 2,000 IU/ml and ALT or AST are elevated, refer to Liver Clinic for a consult regarding management
 - b. If AFP is above the normal range for pregnant women by gestational age, order liver ultrasound and refer to Liver Clinic (See Appendix 1: Bredaki et al Figure 1, below)
4. If HBV DNA is > 200,000 IU/ml and ALT is WNL, start the patient on tenofovir 300 mg/day during the 3rd trimester and continue for 4-6 weeks post-partum to reduce transmission to newborn
 - a. In addition, make sure the newborn receives HBIG and hepatitis B vaccine as soon after birth as is possible, preferably in the delivery room

Post-Partum Care:

1. Perform HBV DNA and LFT at post-partum visit. If ALT is elevated and/or HBV DNA is > 2,000 IU/ml, refer to Liver Clinic
2. Encourage patient to respond to Liver Clinic Reminder letters which are sent every 6 months reminding chronic Hepatitis B patients to have LFT, HBV DNA and AFP testing performed by going to their primary care provider to order and draw their blood.

References:

Viral Hepatitis in Pregnancy. ACOG Practice Bulletin No. 86. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2007;110:941–55. (Re-affirmed 2016)

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018 Apr;67(4):1560-1599.

Bredaki FE, Sciorio C, Wright A, Wright D, Nicolaidis KH. Serum alpha-fetoprotein in the three trimesters of pregnancy: effects of maternal characteristics and medical history. *Ultrasound Obstet Gynecol*. 2015 Jul;46(1):34-41.

Cheung KW, Seto MTY1, So PL, Wong D, Mak ASL, Lau WL, Wang W, Kan ASY, Lee CP, Ng EHY. Optimal timing of hepatitis B virus DNA quantification and clinical predictors for higher viral load during pregnancy. *Acta Obstet Gynecol Scand*. 2019 Apr 25.

Revised 11/20/21 njm
Reviewed 9/21/20 njm
Approved 5/20/19 njm
Written 5/13/19 bmcm

Appendix 1: Bredaki et al Figure 1

Figure 1 Relationship between median (95% CI) levels of serum alpha-fetoprotein (AFP) concentration and gestational age across three trimesters of pregnancy.




Figure 1 Relationship between median (95% CI) levels of serum alpha-fetoprotein (AFP) concentration and gestational age across three trimesters of pregnancy.